Skip to main content

Life Sciences is now live. See how →

Patent Examiner Sergio Coffa

Art Unit 1658 · Peptide & Protein Therapeutics · Tech Center 1600 · 309 applications filed 2021–2026

⚑ Hard · harder than 77% of examiners● Free examiner data

Sergio Coffa is a USPTO patent examiner in Art Unit 1658 (Peptide & Protein Therapeutics) with 309 applications from filing years 2021–2026. Examiner Coffa's allowance rate is 66.7%, below the 82.1% USPTO average for applications filed in the same years. The examiner ranks harder than 77% of examiners. In 2021, decided applications with an examiner interview were allowed 29.7 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 77% of examiners
Easier77th percentileHarder
Allowance rate vs peers
Examiner Coffa66.7%
Art Unit 165854.7%
USPTO average82.1%
Allowance rate
66.7%
▼ USPTO avg 82.1%
Applications
309
filing years 2021–2026
First-action allowance
2.2%
patented with no rejection
Abandoned
20.1%
share of applications
Avg office actions
1.6
USPTO avg 1.3
Days to first OA
755
▲ USPTO 620
RCE rate
24.6%
USPTO 19.7%
Interview rate
15.2%
USPTO 27.5%

Examiner details

  • Art unit1658 · Peptide & Protein Therapeutics
  • Title / gradePrimary Patent Examiner · GS-14
  • Service15 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsCOFFA, SERGIO
Full signatory authority

Examiner Coffa can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions530 · Chemistry: Natural Resins, Peptides or Proteins & Lignins424 · Drug, Bio-Affecting & Body Treating Compositions

How to improve your odds with Examiner Coffa

  • The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 29.7 to 39.3 points.
  • Plan for the timeline. First office action averages 755 days vs the 620-day USPTO norm.
  • Expect a §112. Definiteness & disclosure is the most-issued rejection (202), and applicants overcame it 59.0% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 10.3 to 27.7 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§101 Eligibility24 issued · 66.7% overcome
§102 Novelty128 issued · 51.5% overcome
§103 Obviousness158 issued · 43.7% overcome
§112 Definiteness & disclosure202 issued · 59.0% overcome
How applicants traverse §112 rejections🔒 Members

Of the 49 winning responses to Examiner Coffa's §112 rejections that Boundly has classified, 34 (69%) amended the claims and argued, 8 argued without amending, and 7 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §112 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Coffa?

Draft your response with Examiner Coffa's record and Art Unit 1658's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Coffa.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202323.6%83.3%55.6%+27.7pp
202228.3%73.3%63.0%+10.3pp
202137.2%76.9%54.2%+22.7pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/099258Calcium Independent Phosphatidylserine Binding Compounds for Detecting Phosphatidylserine Positive CellsPatented4🔒 View
17/714896Animal-Free Dietary CollagenPatented3🔒 View
18/433336Methods for Treating Myelin Associated Diseases and Mitochondria Associated DiseasesPatented3🔒 View
17/946816Methods and Compositions for the Treatment of Viral Disease Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)Patented2🔒 View
See all 309 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1658 technology

Antimicrobial & antiviral peptidesAnticancer peptides & proteinsDiabetes & obesity peptidesPeptide compounds & synthesisTop CPC A61K · C07K · C12N
About this examiner. Sergio Coffa examines in Art Unit 1658 (Peptide & Protein Therapeutics, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Sergio Coffa's allowance rate?
Examiner Coffa's allowance rate is 66.7%, compared with 82.1% across the USPTO and 54.7% in Art Unit 1658 for applications filed in the same years. That rate ranks Examiner Coffa harder than 77% of examiners.
Is Examiner Coffa a hard examiner?
Somewhat. Examiner Coffa ranks harder than 77% of examiners, in the 77th difficulty percentile (hard). Examiner Coffa has a 66.7% allowance rate versus 82.1% across the USPTO and 54.7% in Art Unit 1658, 1.6 office actions per application versus 1.3, and an RCE rate of 24.6% versus 19.7% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Coffa?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 3 measured years, by 29.7 to 39.3 percentage points. In 2021, 84.2% of decided applications with an interview were allowed, versus 54.5% of those without.
What is Examiner Coffa's most common rejection?
§112 definiteness & disclosure, issued 202 times in the data. Applicants overcame it 59.0% of the time. Of the 49 winning responses Boundly has classified, 34 amended the claims and argued.
Is an RCE worth filing with Examiner Coffa?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in each of the 3 measured years, by 10.3 to 27.7 percentage points. In 2021, 76.9% of decided applications with an RCE were allowed, versus 54.2% of those without one.
How long until the first office action from Examiner Coffa?
About 755 days on average, versus 620 days across the USPTO for applications filed in the same years.
How do I contact Examiner Sergio Coffa?
Examiner Coffa can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Coffa's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Sergio Coffa, or see an error? Request a correction.